Peter J Meikle Selected Research

Plasmalogens

1/2022	Ether Lipids in Obesity: From Cells to Population Studies.
5/2021	Oral Supplementation of an Alkylglycerol Mix Comprising Different Alkyl Chains Effectively Modulates Multiple Endogenous Plasmalogen Species in Mice.
1/2021	Shark liver oil supplementation enriches endogenous plasmalogens and reduces markers of dyslipidemia and inflammation.
1/2019	HDL Phospholipids, but Not Cholesterol Distinguish Acute Coronary Syndrome From Stable Coronary Artery Disease.
1/2019	Plasmalogens: A potential therapeutic target for neurodegenerative and cardiometabolic disease.
3/2018	Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
1/2017	Baseline serum phosphatidylcholine plasmalogen concentrations are inversely associated with incident myocardial infarction in patients with mixed peripheral artery disease presentations.
11/2016	Corrigendum to "Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice" [Atherosclerosis 243/2 (2015) 598-608].
11/2016	Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia.
4/2016	Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter J Meikle Research Topics

Disease

28	Obesity 01/2022 - 05/2011
26	Insulin Resistance 01/2022 - 05/2011
21	Type 2 Diabetes Mellitus (MODY) 01/2021 - 03/2011
17	Inflammation (Inflammations) 01/2021 - 01/2011
11	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 10/2013
11	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2019 - 06/2011
10	Atherosclerosis 01/2022 - 09/2008
8	Gaucher Disease (Gaucher's Disease) 05/2008 - 01/2002
7	Dyslipidemias (Dyslipidemia) 01/2021 - 01/2013
7	Glycogen Storage Disease Type II (Pompe's Disease) 10/2016 - 01/2002
6	Overweight 01/2021 - 12/2013
6	Fabry Disease (Fabry's Disease) 02/2015 - 10/2004
5	Alzheimer Disease (Alzheimer's Disease) 11/2022 - 01/2018
5	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 11/2017
5	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 12/2015
5	Non-alcoholic Fatty Liver Disease 03/2021 - 01/2013
5	Prediabetic State (Prediabetes) 01/2017 - 01/2013
5	Mucolipidoses (Sialidosis) 06/2011 - 10/2004
5	Mucopolysaccharidoses 06/2011 - 03/2003
5	Mucopolysaccharidosis I (Hurler Syndrome) 08/2006 - 05/2004
4	Heart Diseases (Heart Disease) 01/2022 - 03/2013
4	Metabolic Diseases (Metabolic Disease) 01/2022 - 01/2017
4	Acute Coronary Syndrome 01/2022 - 11/2011
4	Multiple Sulfatase Deficiency Disease (Mucosulfatidosis) 06/2011 - 03/2003
4	Mucopolysaccharidosis III (Sanfilippo Syndrome) 08/2006 - 01/2003
3	Heart Failure 01/2022 - 12/2014
3	Weight Gain 09/2021 - 12/2013
3	Fatty Liver 03/2021 - 01/2019
3	Atrial Fibrillation 01/2021 - 12/2014
3	Liver Diseases (Liver Disease) 01/2021 - 02/2009
3	Myocardial Infarction 01/2018 - 11/2016
3	Infections 01/2017 - 01/2014
3	Hypertension (High Blood Pressure) 01/2014 - 06/2011
3	Glucose Intolerance 01/2013 - 09/2012
3	Metachromatic Leukodystrophy (Sulfatide Lipidosis) 06/2011 - 08/2006
3	alpha-Mannosidosis 09/2006 - 10/2004
2	Hepatocellular Carcinoma (Hepatoma) 04/2022 - 01/2020
2	Neoplasms (Cancer) 04/2022 - 01/2022
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 10/2018
2	Birth Weight (Birth Weights) 01/2021 - 01/2011
2	Fibrosis (Cirrhosis) 01/2020 - 02/2009
2	Rupture 08/2019 - 08/2014
2	Atherosclerotic Plaque (Atheroma) 08/2019 - 12/2015
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 01/2017
2	Stroke (Strokes) 01/2018 - 11/2016
2	Disease Progression 11/2017 - 05/2015
2	Peripheral Arterial Disease 01/2017 - 02/2014
2	Chronic Disease (Chronic Diseases) 10/2016 - 10/2013

Drug/Important Bio-Agent (IBA)

83	LipidsIBA 11/2022 - 05/2008
25	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2002
25	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2002
15	SphingolipidsIBA 01/2022 - 12/2007
14	CholesterolIBA 01/2022 - 04/2008
14	Phospholipids (Phosphatides)FDA LinkGeneric 03/2021 - 01/2011
14	CeramidesIBA 01/2021 - 05/2008
13	Insulin (Novolin)FDA Link 01/2022 - 03/2011
12	PlasmalogensIBA 01/2022 - 12/2013
11	Triglycerides (Triacylglycerol)IBA 04/2022 - 01/2012
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2004
11	EnzymesIBA 10/2016 - 01/2002
8	HDL LipoproteinsIBA 01/2019 - 03/2011
8	OligosaccharidesIBA 09/2006 - 01/2002
7	Fatty Acids (Saturated Fatty Acids)IBA 10/2020 - 03/2011
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2021 - 11/2014
6	Phosphatidylcholines (Phosphatidylcholine)IBA 03/2021 - 05/2013
5	phosphatidylethanolamineIBA 03/2021 - 01/2013
5	oxidized low density lipoproteinIBA 01/2020 - 02/2013
5	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 12/2019 - 01/2012
5	DiglyceridesIBA 04/2016 - 09/2012
4	Apolipoproteins E (ApoE)IBA 11/2022 - 12/2015
4	CytokinesIBA 10/2021 - 01/2011
4	Biological ProductsIBA 09/2021 - 01/2002
4	Glucosylceramides (Glucocerebrosides)IBA 12/2019 - 01/2002
4	Lipoproteins (Lipoprotein)IBA 01/2019 - 09/2013
4	GlycogenIBA 10/2016 - 11/2005
4	Cholesterol Esters (Cholesteryl Esters)IBA 04/2016 - 09/2012
4	GlycosphingolipidsIBA 04/2008 - 10/2004
4	Iduronidase (alpha-L-Iduronidase)IBA 01/2006 - 05/2004
3	dihydroceramideIBA 01/2019 - 01/2013
3	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2017 - 01/2013
3	dihexosylceramideIBA 01/2015 - 05/2008
3	alpha-Glucosidases (Acid Maltase)IBA 08/2006 - 11/2005
3	GlycosaminoglycansIBA 05/2004 - 03/2003
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2022 - 12/2019
2	sphingosine kinaseIBA 10/2021 - 12/2012
2	Nonesterified Fatty Acids (NEFA)IBA 03/2021 - 01/2012
2	Bile Acids and Salts (Bile Acids)IBA 01/2021 - 02/2009
2	Branched-Chain Amino AcidsIBA 01/2021 - 10/2018
2	HDL CholesterolIBA 01/2021 - 05/2014
2	Carrier Proteins (Binding Protein)IBA 10/2020 - 09/2008
2	SphingomyelinsIBA 12/2019 - 05/2008
2	Amyloid beta-PeptidesIBA 12/2019 - 01/2018
2	Therapeutic UsesIBA 10/2019 - 01/2017
2	CarbohydratesIBA 01/2019 - 09/2014
2	G(M3) GangliosideIBA 08/2017 - 05/2008
2	C-Reactive ProteinIBA 01/2017 - 12/2013
2	GlucosidasesIBA 10/2016 - 02/2012

Therapy/Procedure

10	Therapeutics 05/2021 - 01/2002
6	Enzyme Replacement Therapy 05/2008 - 12/2003
4	Castration 01/2022 - 11/2017